{"title":"评估尼妥珠单抗加吉西他滨-顺铂治疗 aUC 在中国的成本效益。","authors":"Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan","doi":"10.3389/fphar.2024.1382342","DOIUrl":null,"url":null,"abstract":"<p><strong>Aims: </strong>Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.</p><p><strong>Methods: </strong>A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.</p><p><strong>Results: </strong>The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.</p><p><strong>Conclusion: </strong>Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.</p>","PeriodicalId":12491,"journal":{"name":"Frontiers in Pharmacology","volume":"15 ","pages":"1382342"},"PeriodicalIF":4.4000,"publicationDate":"2024-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573544/pdf/","citationCount":"0","resultStr":"{\"title\":\"Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.\",\"authors\":\"Kehui Meng, Heng Xiang, Meiyu Wu, Ouyang Xie, Andong Li, Chongqing Tan, Xiaomin Wan\",\"doi\":\"10.3389/fphar.2024.1382342\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Aims: </strong>Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.</p><p><strong>Methods: </strong>A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.</p><p><strong>Results: </strong>The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.</p><p><strong>Conclusion: </strong>Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.</p>\",\"PeriodicalId\":12491,\"journal\":{\"name\":\"Frontiers in Pharmacology\",\"volume\":\"15 \",\"pages\":\"1382342\"},\"PeriodicalIF\":4.4000,\"publicationDate\":\"2024-11-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11573544/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Frontiers in Pharmacology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.3389/fphar.2024.1382342\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Frontiers in Pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.3389/fphar.2024.1382342","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Evaluating nivolumab plus gemcitabine-cisplatin's cost-effectiveness for aUC in China.
Aims: Assessing the cost-effectiveness of Nivolumab with Gemcitabine-Cisplatin for Advanced Urothelial Carcinoma (aUC) treatment from the perspective of Chinese payers.
Methods: A Markov model assessed economic outcomes, estimating health outcomes in quality-adjusted life years (QALYs). One-way and probabilistic sensitivity analyses were conducted to assess the impact of uncertainties on the results.
Results: The base-case analysis showed Nivolumab plus Gemcitabine-Cisplatin yielded 0.59 QALYs at an extra cost of $78,780.61, leading to an incremental cost-effectiveness ratios (ICER) of $133,526.46/QALY. One-way sensitivity analysis highlighted Nivolumab's cost as the key factor, while probabilistic sensitivity analysis showed a 0% chance of cost-effectiveness for Nivolumab plus Gemcitabine-Cisplatin in aUC treatment.
Conclusion: Nivolumab plus Gemcitabine-Cisplatin is not cost-effective in the treatment of aUC.
期刊介绍：
Frontiers in Pharmacology is a leading journal in its field, publishing rigorously peer-reviewed research across disciplines, including basic and clinical pharmacology, medicinal chemistry, pharmacy and toxicology. Field Chief Editor Heike Wulff at UC Davis is supported by an outstanding Editorial Board of international researchers. This multidisciplinary open-access journal is at the forefront of disseminating and communicating scientific knowledge and impactful discoveries to researchers, academics, clinicians and the public worldwide.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
